12:00 AM
 | 
Aug 15, 2011
 |  BC Week In Review  |  Company News  |  Deals

AMAG Pharmaceuticals, MSMB Capital Management LLC deal

AMAG said its board unanimously rejected an unsolicited offer from shareholder MSMB Capital to acquire AMAG for $18 per share, or about $380.9 million in...

Read the full 104 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >